Palvella Therapeutics, Inc. (PVLA)
NASDAQ · Manufacturing · Pharmaceutical preparations
$137.92−$8.15 (−5.58%) on the dayAs of the close; data may be delayed.
PVLA price, last 12 months
Key stats
- Previous close
- $146.07
- Open
- $147.02
- Day range
- $137.86 – $147.44
- 52-week range
- $57.33 – $161.38
- Volume
- 137.4K
- Avg volume (20 days)
- 209.4K
- Market cap
- $2.2B
Performance
1W−8.4%
1M−10.6%
3M−6.9%
6M+17.3%
YTD+31.8%
1Y+134.3%
vs S&P 500, 1Y+117.5 pts
Technicals and fundamentals
About Palvella Therapeutics, Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $2.2B